Biotricity (BTCY) Competitors $0.47 -0.03 (-6.20%) As of 12:10 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock BTCY vs. MDAI, DXR, SPAI, PTHL, ECOR, LYRA, NEPH, POCI, COCH, and PYPDShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Spectral AI (MDAI), Daxor (DXR), Safe Pro Group Inc. Common Stock (SPAI), Pheton Holdings Ltd Class A Ordinary Shares (PTHL), electroCore (ECOR), Lyra Therapeutics (LYRA), Nephros (NEPH), Precision Optics (POCI), Envoy Medical (COCH), and PolyPid (PYPD). These companies are all part of the "medical equipment" industry. Biotricity vs. Its Competitors Spectral AI Daxor Safe Pro Group Inc. Common Stock Pheton Holdings Ltd Class A Ordinary Shares electroCore Lyra Therapeutics Nephros Precision Optics Envoy Medical PolyPid Spectral AI (NASDAQ:MDAI) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends. Is MDAI or BTCY more profitable? Spectral AI has a net margin of -40.78% compared to Biotricity's net margin of -80.42%. Company Net Margins Return on Equity Return on Assets Spectral AI-40.78% N/A -77.87% Biotricity -80.42%N/A -188.47% Do analysts recommend MDAI or BTCY? Spectral AI presently has a consensus target price of $4.75, suggesting a potential upside of 126.19%. Given Spectral AI's stronger consensus rating and higher possible upside, research analysts clearly believe Spectral AI is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spectral AI 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk and volatility, MDAI or BTCY? Spectral AI has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Does the MarketBeat Community prefer MDAI or BTCY? Spectral AI received 7 more outperform votes than Biotricity when rated by MarketBeat users. Likewise, 87.50% of users gave Spectral AI an outperform vote while only 0.00% of users gave Biotricity an outperform vote. CompanyUnderperformOutperformSpectral AIOutperform Votes787.50% Underperform Votes112.50%BiotricityOutperform VotesNo VotesUnderperform Votes2100.00% Does the media prefer MDAI or BTCY? In the previous week, Spectral AI had 4 more articles in the media than Biotricity. MarketBeat recorded 4 mentions for Spectral AI and 0 mentions for Biotricity. Spectral AI's average media sentiment score of 0.89 beat Biotricity's score of 0.00 indicating that Spectral AI is being referred to more favorably in the media. Company Overall Sentiment Spectral AI Positive Biotricity Neutral Do institutionals and insiders hold more shares of MDAI or BTCY? 67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 3.9% of Biotricity shares are owned by institutional investors. 30.7% of Spectral AI shares are owned by insiders. Comparatively, 10.1% of Biotricity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, MDAI or BTCY? Biotricity has lower revenue, but higher earnings than Spectral AI. Spectral AI is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpectral AI$29.96M1.77-$20.85M-$0.54-3.89Biotricity$12.06M0.97-$14.09M-$1.08-0.43 SummarySpectral AI beats Biotricity on 15 of the 18 factors compared between the two stocks. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.68M$4.37B$5.59B$8.63BDividend YieldN/A42.67%5.28%4.18%P/E Ratio-0.4329.0127.2120.00Price / Sales0.9771.17411.62157.76Price / CashN/A51.0838.2534.64Price / Book-0.365.837.114.70Net Income-$14.09M$67.63M$3.24B$248.05M7 Day Performance-18.84%0.38%2.54%2.51%1 Month Performance-8.80%15.30%8.76%6.17%1 Year Performance-48.49%18.29%31.37%13.72% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.47-6.2%N/A-48.5%$11.68M$12.06M-0.4340Gap UpMDAISpectral AI3.6507 of 5 stars$1.74+6.7%$4.75+173.0%+19.9%$44.05M$29.96M-2.6883News CoverageShort Interest ↓Gap UpDXRDaxor4.0103 of 5 stars$8.63+3.0%$25.00+189.7%-1.8%$41.74M$2.13M0.0037Positive NewsGap DownSPAISafe Pro Group Inc. Common StockN/A$2.64-9.0%N/AN/A$40.05M$2.05M-3.2611News CoveragePositive NewsGap UpPTHLPheton Holdings Ltd Class A Ordinary SharesN/A$6.02-4.3%N/AN/A$39.62M$448.20K0.0011High Trading VolumeECORelectroCore2.6049 of 5 stars$5.18+3.4%$25.50+392.3%-14.2%$38.44M$26.46M-2.8350LYRALyra Therapeutics3.0507 of 5 stars$27.58+36.2%$100.00+262.6%-12.9%$36.54M$1.19M-18.5150Short Interest ↓Analyst RevisionHigh Trading VolumeNEPHNephros1.9061 of 5 stars$3.27+4.5%$5.00+52.9%+71.9%$34.66M$15.52M-36.3330Short Interest ↑Gap UpHigh Trading VolumePOCIPrecision Optics0.3301 of 5 stars$4.45flatN/A-22.5%$34.11M$17.63M-6.9580Short Interest ↑Gap DownCOCHEnvoy Medical2.3334 of 5 stars$1.55+3.3%$9.25+496.8%-41.8%$33.06M$212K-1.1234News CoverageShort Interest ↑Gap DownPYPDPolyPid3.1507 of 5 stars$3.14+6.4%$11.33+260.9%-21.0%$32MN/A-0.6380Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Spectral AI Alternatives Daxor Alternatives Safe Pro Group Inc. Common Stock Alternatives Pheton Holdings Ltd Class A Ordinary Shares Alternatives electroCore Alternatives Lyra Therapeutics Alternatives Nephros Alternatives Precision Optics Alternatives Envoy Medical Alternatives PolyPid Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTCY) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTCY Stock Free BTCY Stock Alerts